(Q56977976)

2

0 references

Marc Humbert

object named as

Marc Humbert

5

0 references

Stephen C. Mathai

3

object named as

Stephen C. Mathai

0 references

author name string

Paul M. Hassoun

Clinical Reviews in Allergy & Immunology

4

0 references

publication date

12 January 2010

0 references

published in

0 references

volume

40

0 references

issue

2

0 references

page(s)

104-116

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s12016-009-8194-2

0 references

cites work

Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Systemic sclerosis: the susceptible host (genetics and environment).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Scleroderma. Clinical problems. The lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Changes in causes of death in systemic sclerosis, 1972-2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

The many faces of scleroderma sine scleroderma: a literature review focusing on cardiopulmonary complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Autoantibody to U3 Nucleolar Ribonucleoprotein (Fibrillarin) In Patients with Systemic Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Autoantibodies in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Interstitial lung disease in systemic sclerosis: a simple staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Computed tomography of chronic diffuse infiltrative lung disease. Part 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Cyclophosphamide versus placebo in scleroderma lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

New developments in scleroderma interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Severe restrictive lung disease in systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Regulation of PDGF and its receptors in fibrotic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Outcomes of lung transplantation in patients with scleroderma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Pulmonary arterial hypertension in France: results from a national registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Predictors of end stage lung disease in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Isolated pulmonary hypertension in scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Systemic sclerosis associated pulmonary hypertension: improved survival in the current era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

21 January 2018

Scleroderma epidemiology

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Clinical differences between idiopathic and scleroderma-related pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Tricuspid annular displacement predicts survival in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Endothelial dysfunction in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Inflammation in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Immunosuppressive therapy in lupus- and mixed connective tissue disease–associated pulmonary arterial hypertension: A retrospective analysis of twenty-three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Regulatory functions of the vascular endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Pulmonary disease in progressive systemic sclerosis. A complication of gastroesophageal reflux and occult aspiration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Interstitial lung disease and gastroesophageal reflux.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Pulmonary function and gastroesophageal reflux in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Does interstitial lung disease predispose to lung cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Risk of cancer in patients with scleroderma: a population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Scleroderma and malignancy: an epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Lung cancer associated with several connective tissue diseases: with a review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Cancer and systemic sclerosis. An epidemiologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Risk of malignancy in scleroderma: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

The spectrum of scleroderma lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Muscle disease in progressive systemic sclerosis. diagnostic and therapeutic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Muscle abnormalities in scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Lung function abnormalities and decline of spirometry in scleroderma: an overrated danger?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Small airways in progressive systemic sclerosis (PSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Bronchiolitis obliterans in a patient with localized scleroderma treated with D-penicillamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8194-2

Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance

21 January 2018

1 reference

12 December 2020

Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease

1 reference

12 December 2020

Sildenafil for pulmonary arterial hypertension associated with connective tissue disease

1 reference

12 December 2020

Age and risk of pulmonary arterial hypertension in scleroderma

1 reference

12 December 2020

Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results

1 reference

12 December 2020

Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.

1 reference

12 December 2020

Antibodies to histone (H2A-H2B)-DNA complexes in the absence of antibodies to double-stranded DNA or to (H2A-H2B) complexes are more sensitive and specific for scleroderma-related disorders than for lupus

1 reference

12 December 2020

Esophageal involvement and pulmonary manifestations in systemic sclerosis

1 reference

12 December 2020

Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease

1 reference

12 December 2020

Spontaneous pneumothorax in a patient with systemic sclerosis

1 reference

12 December 2020

Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function.

1 reference

12 December 2020

Primary pulmonary hypertension

1 reference

12 December 2020

Lung function abnormalities in different connective tissue diseases

1 reference

12 December 2020

Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study

1 reference

12 December 2020

Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma

1 reference

12 December 2020

Relationship between cutaneous and pulmonary involvement in systemic sclerosis

1 reference

12 December 2020

Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension

1 reference

12 December 2020

Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis

1 reference

12 December 2020

An unusual presentation of progressive systemic sclerosis

1 reference

12 December 2020

Predictors of survival in systemic sclerosis (scleroderma)

1 reference

12 December 2020

Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases

1 reference

12 December 2020

Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: A controlled study of 100 consecutive patients

1 reference

12 December 2020

Decreased nailfold capillary density in limited scleroderma with pulmonary hypertension

1 reference

12 December 2020

High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis.

1 reference

12 December 2020

Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL Cooperative Group Steering Committee

1 reference

12 December 2020

Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings

1 reference

12 December 2020

Scleroderma (systemic sclerosis): classification, subsets and pathogenesis

1 reference

12 December 2020

Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma

1 reference

12 December 2020

Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography

1 reference

12 December 2020

Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma.

1 reference

12 December 2020

Progressive systemic sclerosis presenting with spontaneous pneumothorax

1 reference

12 December 2020

Lung function in progressive systemic sclerosis is dominated by poorly compliant lungs and stiff airways.

1 reference

12 December 2020

Determinants of pulmonary arterial hypertension in scleroderma

1 reference

12 December 2020

Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.

1 reference

12 December 2020

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

1 reference

12 December 2020

Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors

1 reference

12 December 2020

Scleroderma patients with combined pulmonary hypertension and interstitial lung disease.

1 reference

12 December 2020

Progressive systemic sclerosis subgroups: variable pulmonary features

1 reference

12 December 2020

Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study

1 reference

12 December 2020

Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients

1 reference

12 December 2020

Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis

1 reference

12 December 2020

Determinants of morbidity and mortality of systemic sclerosis in Canada

1 reference

12 December 2020

Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis

1 reference

12 December 2020

Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients

1 reference

12 December 2020

Cyclophosphamide for scleroderma lung disease

1 reference

12 December 2020

Relationship between abnormalities on high-resolution CT and pulmonary function in systemic sclerosis

1 reference

12 December 2020

Right heart function and scleroderma: insights from tricuspid annular plane systolic excursion

1 reference

12 December 2020

Bilateral spontaneous pneumothorax in systemic sclerosis--report of two cases

1 reference

12 December 2020

Right heart function in scleroderma: insights from myocardial Doppler tissue imaging

1 reference

12 December 2020

Bosentan therapy for pulmonary arterial hypertension

1 reference

12 December 2020

Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis

1 reference

12 December 2020

Nonspecific interstitial pneumonia in collagen vascular diseases: comparison of the clinical characteristics and prognostic significance with usual interstitial pneumonia

1 reference

12 December 2020

Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance

1 reference

12 December 2020

Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients

1 reference

12 December 2020

Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis

1 reference

12 December 2020

Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease

1 reference

12 December 2020

Severe organ involvement in systemic sclerosis with diffuse scleroderma

1 reference

12 December 2020

Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis

1 reference

12 December 2020

Lung transplantation and systemic sclerosis

1 reference

12 December 2020

A study of the frequency of pericardial and pleural effusions in scleroderma.

1 reference

12 December 2020

Immunosuppressive Therapy in Connective Tissue Diseases-Associated Pulmonary Arterial Hypertension

1 reference

12 December 2020

Connective Tissue Disease–associated Pulmonary Arterial Hypertension in the Modern Treatment Era

1 reference

12 December 2020

Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma

1 reference

12 December 2020

Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody.

1 reference

12 December 2020